20,611 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Wrapmanager Inc.

Wrapmanager Inc. acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 20,611 shares of the biopharmaceutical company’s stock, valued at approximately $220,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. purchased a new position in shares of Amicus Therapeutics in the second quarter worth about $8,386,000. M&G Plc boosted its holdings in shares of Amicus Therapeutics by 12.4% during the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after purchasing an additional 82,728 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of Amicus Therapeutics by 7.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 7,304 shares in the last quarter. Fiera Capital Corp increased its holdings in shares of Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after purchasing an additional 58,113 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its position in Amicus Therapeutics by 24.2% during the second quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock worth $2,483,000 after buying an additional 48,802 shares in the last quarter.

Analyst Ratings Changes

Several analysts have issued reports on the company. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Bank of America upped their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Guggenheim lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Stock Down 1.4 %

Amicus Therapeutics stock opened at $9.52 on Wednesday. The company has a market capitalization of $2.84 billion, a PE ratio of -28.00 and a beta of 0.68. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The firm has a 50 day moving average price of $10.92 and a 200 day moving average price of $10.60.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have sold 30,401 shares of company stock worth $352,038. 2.20% of the stock is currently owned by company insiders.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.